Table 1.

CSF findings in patients with post-COVID MOGAD disease

Variables	CSF protein				CSF cell count				CSF lymphocyte %
	Low (≤ 45)	High (> 45)	N (%)	p	No (≤ 5)	Yes (> 5)	N (%)	p	≤ 50%	> 50%	N (%)	p
Age
50+	0 (0)	1 (100)	1 (14.3)	0.4	0 (0)	1 (100)	1 (20)	1	No CSF	No CSF		NA
< 50	4 (67)	2 (33)	6 (85.7)		2 (50)	2 (50)	4 (80)		3(75)	1(25)	4(100)
Gender
Female	1 (50)	1 (50)	2 (28.6)	1	1 (100)	0 (0)	1 (20)	0.4	1 (100)	0 (0)	1 (25)	1
Male	3 (60)	2 (40)	5 (71.4)		1 (25)	3 (75)	4 (80)		2 (67)	1 (33)	3 (75)
COVID-19 severitya
Non-severe	3 (50)	3 (50)	6 (85.7)	1	1 (25)	3 (75)	4 (80)	0.4	2 (67)	1 (33)	3 (75)	1
Severe	1 (100)	0 (0)	1 (14.3)		1 (100)	0 (0)	1 (20)		1 (100)	0 (0)	1 (25)
Fatality
Non-fatal	4 (57.1)	3 (42.9)	7 (100)	NA	2 (40)	3 (60)	5 (100)	NA	3 (75)	1 (25)	4 (100)	NA
Fatal	0	0	0		0	0	0		0	0	0

CSF cerebrospinal fluid, NA not applicable

P values were calculated from Fisher’s exact test. All observations were non-fatal and thus a Fisher’s exact test was not available between fatality and the outcomes of interest

^aSeverity based on the IDSA/ATS guidelines